Action CVR Medical - CVM

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,015

Prix Achat

0,015

Prix Vente

0,02

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

0,015

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

Statistically Significant Findings Published in Prestigious Journal of International Immunopharmacology VIENNA, Va., Feb. 22...

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

Company Ends Quarter in Strongest Financial Condition Ever VIENNA, Va., Feb. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM...

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

VIENNA, Va., Feb. 3 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) announced that Geert Kersten, Chief Executive Officer, will...

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

VIENNA, Va., Jan. 15 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM), a late-stage oncology company and a developer of vaccines...

CEL-SCI Corporation Announces 2009 Financial Results

Company Ends Fiscal Year in Strongest Financial Condition Ever; Receives Clean and Unqualified Audit Opinion VIENNA, Va., Jan. 13...

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

Facility Is Also Expected to Generate Revenue Through Contract Manufacturing VIENNA, Va., Jan. 11 /PRNewswire-FirstCall/ -- CEL-SCI Corporation...

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

VIENNA, Va., Dec. 1 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a late-stage oncology company and a developer of vaccines...

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

VIENNA, Va., Nov. 18 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention...

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

STUDIES SUPPORTIVE OF ROLE THAT TECHNOLOGY CAN PLAY IN TREATMENT OF H1N1 HOSPITALIZED PATIENTS VIENNA, Va., Nov. 9 /PRNewswire-FirstCall/...

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

VIENNA, Va., Nov. 6 /PRNewswire/ -- CEL-SCI Corporation (NYSE Amex: CVM), a developer of vaccines and therapeutics for the prevention and...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

CVM - Frequently Asked Questions (FAQ)

What is the current CVR Medical share price?

The current share price of CVR Medical is $ 0,015

What is the 1 year trading range for CVR Medical share price?

CVR Medical has traded in the range of $ 0,00 to $ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
OVL.HOlivier Ventures Inc	$ 0,02 (300,00%)	49,1k
BYM.HBaymount Incorporated	$ 0,015 (200,00%)	1 000
GNFIGenifi Inc	$ 0,01 (100,00%)	1 000
WT.HWangton Capital Corp	$ 0,04 (100,00%)	1,5k
AGH.HCanadian Silver Hunter Inc	$ 0,04 (100,00%)	2k
PORPortofino Resources Inc	$ 0,005 (-50,00%)	126k
CLMConsolidated Lithium Metals Inc	$ 0,005 (-50,00%)	2k
ECAP.PEndurance Capital Corp	$ 0,025 (-37,50%)	1 000
SCLTSearchlight Resources Inc	$ 0,01 (-33,33%)	248k
CRBCariboo Rose Resources Ltd	$ 0,035 (-30,00%)	5k
PERPeruvian Metals Corp	$ 0,02 (0,00%)	1,68M
BYNBanyan Gold Corp	$ 0,225 (2,27%)	1,52M
SLGSan Lorenzo Gold Corp	$ 0,31 (-3,13%)	1,47M
GSVRGuanajuato Silver Company Ltd	$ 0,16 (-5,88%)	1,09M
GPUSAlset AI Ventures Inc	$ 0,08 (6,67%)	1M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

CVR Medical Corporation (CVM)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

CVM Dernières nouvelles

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

CEL-SCI Corporation Announces 2009 Financial Results

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

CVM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

CVR Medical Corporation (CVM) Cours

CVR Medical Corporation (CVM)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

CVM Dernières nouvelles

CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis

CEL-SCI Corporation Reports First Quarter 2010 Financial Results

CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference

CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations

CEL-SCI Corporation Announces 2009 Financial Results

CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine

CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine

CEL-SCI Announces Start of First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients

CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response

CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns

CVM - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS